Agenda Released | Frost & Sullivan Summit 2026 – Life Science New Investment Forum Open for Registration

02

The Frost & Sullivan Growth, Innovation and Leadership Best Practices Award (referred to as the GIL Award) aims to recognize outstanding companies that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development worldwide, the authority and fairness of this award have been widely recognized by the investment and financial communities, as well as within the industry. To date, over 5,000 excellent companies have been honored globally.

2026 marks the 65th anniversary of Frost & Sullivan. Frost & Sullivan China will continue to study numerous entrepreneurial and investment success stories in high-tech and strategic emerging industries. It will conduct objective analysis and comprehensive evaluation of the innovation capabilities, business models, founding teams, technical abilities, and future prospects of participating companies. Together with a professional judging committee, several leading biotech companies will be selected. The winners of the 2026 GIL Award will be announced during this conference, along with the celebration of Frost & Sullivan's 65th anniversary and the 20th anniversary of Frost & Sullivan China.

At this conference, Frost & Sullivan will release seven blue books covering Hong Kong Stock Market 18A, biopharmaceutical exports, gene therapy, brain-computer interfaces, digital intelligent medical imaging, AI healthcare, and synthetic biology. These books focus on the forefront of global technological changes and industrial restructuring, providing deep insights into innovation trends and investment directions in the life and health sector.

English and Chinese version of the "2026 Hong Kong Stock Market 18A Biotech Industry Development Blue Book"

With the acceleration of innovation drug research and development, the continuous improvement of Hong Kong Stock Exchange's capital market systems, and multiple factors in the transformation and upgrading of China's biopharmaceutical industry, the 18A rules have entered a mature development cycle of standardization and normalization after pilot trials. The reform of China's biopharmaceutical capital market has been fully implemented. As a special listing channel for unprofitable biotech companies, the 18A system breaks down barriers between innovation research and development and the capital market, helping domestic pharmaceutical companies achieve full-chain breakthroughs from clinical development to industrialization.

Under these circumstances, Frost & Sullivan has compiled this blue book by integrating vast amounts of data from the global biotech secondary market, investment and financing in both primary and secondary markets, and IPO issuance transactions. It reviews the ten-year cycle changes in the global biopharmaceutical capital market and the evolution path of 18A policies, breaks down the 18A industry map, popular innovation tracks, and core fundamentals of listed companies; it quantifies the valuation and operating data throughout the entire process from Pre-IPO financing, new share issuance to post-IPO secondary market performance, and explores diversified financing models for biopharmaceuticals through the innovation of Hong Kong RWA asset tokenization. It also includes authoritative lists of annual IPO intermediaries, listed companies, and institutional investors, providing a deep analysis of growth prospects, corporate pipeline value, and commercialization potential in each segment. This provides quantitative data, industry insights, and decision-making basis for biopharmaceutical companies, primary and secondary investment institutions, capital market intermediaries, and industry regulators.

English and Chinese version of the "2026 China Biopharmaceutical Internationalization Development Blue Book"

China's biopharmaceutical companies' "export" is an inevitable choice for the Chinese innovation drug industry to actively participate in global industrial division of labor and seek larger market space and higher value realization after completing early capacity accumulation. In the past, Chinese biopharmaceutical companies relied more on local clinical resources, engineer advantages, and rapid iteration capabilities to start innovation. However, as local market competition intensifies, payment constraints increase, and similar pipelines multiply, internationalization becomes an important direction for companies to break through growth boundaries, verify innovation value, and enhance capital recognition. Meanwhile, global pharmaceutical companies are re-evaluating Chinese innovation forces, considering Chinese companies as important research cooperation partners, asset sources, and industrial chain partners. Based on this, Frost & Sullivan releases the "2026 China Biopharmaceutical Internationalization Development Blue Book" to systematically outline the stage characteristics, driving factors, main paths, and future trends of internationalization development of Chinese biopharmaceutical companies. It will discuss the long-term value and development blueprint of the Chinese biopharmaceutical industry entering global markets with industry participants, investors, and stakeholders.

English and Chinese version of the "2026 Global Gene Therapy Industry Development Blue Book"

Driven by continuous technological breakthroughs, improved regulatory frameworks, and capital investment, the gene therapy industry is accelerating from an early technical exploration stage to commercialization. Notably, China's "15th Five-Year Plan" has included bio-manufacturing as one of the core directions of strategic emerging industries, and gene therapy has been identified as a key area requiring "key progress." Under the "15th Five-Year" macro-strategy, gene therapy is no longer just a market behavior driven by technology exploration and capital, but has become a key component of national bieconomic competitiveness, requiring systematic improvements in carrier technology, production process upgrades, clinical conversion efficiency, and regulatory system perfection. However, the industry still faces systemic challenges such as complex production processes, insufficient large-scale production capacity, high shell rate and cost pressure, long-term data verification, and imperfect payment system. In this context, Frost & Sullivan aims to provide forward-looking market insights and strategic decision-making references for the development stage, technical system, and industrial chain structure of the gene therapy industry, as well as an in-depth analysis of key process barriers, commercialization paths, and market space, offering insights for all parties in the industry.

English and Chinese version of the "2026 Global Brain-Computer Interface Industry Development White Paper"

Currently, innovative achievements in the field of brain-computer interfaces in China are continuously emerging, and the industry is developing rapidly, becoming an important area for the deep integration of technological innovation and industrial innovation. By establishing a full-chain ecosystem of "technical innovation—scenario application—industrial clustering" and prioritizing review mechanisms, China is accelerating its transition from key technology breakthroughs to global industry leadership, creating new advantages for Chinese enterprises in international competition. In this context, Frost & Sullivan aims to provide forward-looking market insights and strategic decision-making references for all parties in the industry chain by systematically outlining the development stage, structural characteristics, and evolution path of the industry, as well as an in-depth analysis of the current situation and market space in key application areas.

English and Chinese version of the "2026 Global Digital Intelligent Medical Imaging Ecosystem Industry Development Blue Book"

As artificial intelligence reshapes various industries at an unprecedented speed, the healthcare sector is undergoing a profound transformation from "experience-driven" to "data intelligence." In this transformation, AI medical imaging is undoubtedly one of the most highly focused and clinically valuable sectors. However, this integration is triggering deeper changes: AI is no longer just the "second pair of eyes" of radiologists, but has become a decisive factor in the digital intelligence evolution of the medical imaging ecosystem. Starting from the current construction status and pain points of the medical imaging ecosystem, we will analyze how medical imaging AI can empower the medical imaging ecosystem in the era of AGI, and then look ahead to the future development of the digital intelligent imaging ecosystem. Through this white paper, we hope to enable the public to better understand the development of the medical imaging ecosystem and how AI medical imaging can truly become a partner and digital doppelgänger in doctors' diagnosis and treatment processes.

English and Chinese version of the "2026 Global AI Healthcare Industry Development Blue Book"

In recent years, with the continuous development of next-generation information technologies such as big data, cloud computing, and the Internet of Things, especially the breakthroughs in generative artificial intelligence and large model technologies, artificial intelligence (AI) has entered a stage of accelerated application worldwide. The healthcare industry, as a data-intensive and highly specialized field, is becoming an important scenario for deep integration of artificial intelligence. AI is making technological progress in areas such as medical imaging, auxiliary diagnosis, disease management, drug research and development, and hospital operation management, promoting the upgrading of the healthcare service system towards intelligence and precision.

Driven by multiple factors including policy support, technological maturity, and capital attention, China's AI healthcare industry is in a critical period of transitioning from technical validation to large-scale implementation. Industrial chain collaboration is deepening, niche sectors are evolving rapidly, and the industry competition pattern is becoming clearer. How to seize development opportunities during the restructuring of the industrial structure and the upgrade of technical paths has become a core issue for industry participants.

English and Chinese version of the "2026 Global Synthetic Biology Industry Development White Paper"

Synthetic biology is widely defined by academia and industry as the third major life science revolution following the discovery of the DNA double helix structure and the genome technology revolution. The 2026 Government Work Report clearly states the need to cultivate and strengthen emerging and future industries, and promote bio-manufacturing as a new economic growth point. Synthetic biology and bio-manufacturing are no longer just technical issues, but a triple intersection of national security (supply chain autonomy), climate agenda (Dual Carbon/Zero Carbon Negative Carbon), and economic increment (new quality productive forces). Based on long-term insights into global cutting-edge technologies and bio-manufacturing industries, Frost & Sullivan launches the "2026 Global Synthetic Biology Industry Development White Paper," providing a global perspective through an industrial chain panorama, country/region comparison, and triple lens of regulation-technology-business to deeply understand industry trends.

Life Science New Investment Forum

Event consultation | Sponsorship cooperation | Attendance consultation

📞 Conference consultation hotline:

021-3209-6800 ext. 8672

📧 Conference consultation email:

gil@frostchina.com